中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides

文献类型：期刊论文

作者Liu, Ruiqi3; Li, Hong3; Qiu, Yihua3; Liu, Hongguang3; Cheng, Zhen1,2
刊名PHARMACEUTICALS
出版日期2022-11-01
卷号15期号:11页码:18
关键词hepatocellular carcinoma transarterial radioembolization radioactive seed implantation radioimmunotherapy
DOI10.3390/ph15111339
通讯作者Liu, Hongguang(simonliu@mail.neu.edu.cn) ; Cheng, Zhen(zcheng@simm.ac.cn)
英文摘要As the third leading cause of cancer death worldwide, hepatocellular carcinoma (HCC) is characterized by late detection, difficult diagnosis and treatment, rapid progression, and poor prognosis. Current treatments for liver cancer include surgical resection, radiofrequency ablation, liver transplantation, chemotherapy, external radiation therapy, and internal radionuclide therapy. Radionuclide therapy is the use of high-energy radiation emitted by radionuclides to eradicate tumor cells, thus achieving the therapeutic effect. Recently, with the continuous development of biomedical technology, the application of radionuclides in treatment of HCC has progressed steadily. This review focuses on three types of radionuclide-based treatment regimens, including transarterial radioembolization (TARE), radioactive seed implantation, and radioimmunotherapy. Their research progress and clinical applications are summarized. The advantages, limitations, and clinical potential of radionuclide treatment of HCC are discussed.
WOS关键词TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION ; INTRAARTERIAL INJECTION ; Y-90 RADIOEMBOLIZATION ; METUXIMAB INJECTION ; RADIATION-THERAPY ; PHASE-I ; MICROSPHERES ; LIPIODOL ; SURVIVAL ; I-125
资助项目National Natural Science Foundation of China[U2267221] ; Shanghai Municipal Science and Technology Major Project
WOS研究方向Pharmacology & Pharmacy
语种英语
出版者MDPI
WOS记录号WOS:000882306700001
源URL[http://119.78.100.183/handle/2S10ELR8/302879]  
专题新药研究国家重点实验室
通讯作者Liu, Hongguang; Cheng, Zhen
作者单位1.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Peoples R China
2.Chinese Acad Sci, Mol Imaging Ctr, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
3.Northeastern Univ, Coll Life & Hlth Sci, Inst Mol Med, Shenyang 110000, Peoples R China
推荐引用方式
GB/T 7714		 Liu, Ruiqi,Li, Hong,Qiu, Yihua,et al. Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides[J]. PHARMACEUTICALS,2022,15(11):18.
APA Liu, Ruiqi,Li, Hong,Qiu, Yihua,Liu, Hongguang,&Cheng, Zhen.(2022).Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides.PHARMACEUTICALS,15(11),18.
MLA Liu, Ruiqi,et al."Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides".PHARMACEUTICALS 15.11(2022):18.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。